Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global company and a leader in the treatment of cardiovascular diseases, announced the U.S. Food and Drug Administration (FDA) clearance of its newest generation C5 Heart-Lung Machine (HLM).

A Heart-Lung Machine is a sophisticated piece of medical equipment that provides blood oxygenation and circulation to organs and the brain while the patient's heart and lungs are temporarily stopped during a cardio-thoracic surgical procedure.

Sorin's C5 HLM is the culmination of over 25 years of experience in extracorporeal perfusion system design and manufacturing.

The C5HLM builds on the state-of-the-art technology and proven interface of Sorin's S5 industry-standard HLM, while being lighter in weight and more compact. The C5has excellent manoeuvrability and a well thought-out, logical structure, functional ergonomic design and reliable safety systems. Its solid, brushed stainless steel housing reflects the product´s high quality.

With the C5HLM, Sorin obtained FDA clearance within one month of submission, the shortest clearance time for a heart lung machine on company record. The introduction of the C5to the US market will further strengthen Sorin Group's world leading position in the cardiopulmonary bypass market.

"The C5 HLM provides another example of Sorin Group's commitment to developing solutions that meet the needs of both patients and clinicians. Our focus on delivering product and service excellence helps maintain our worldwide leading position", said Michel Darnaud, President, Cardiopulmonary Business Unit and Intercontinental, Sorin Group.

The C5 HLM will be showcased for the first time in the USA at CREF - Cardiothoracic Surgery Symposium - in Newport Beach, CA on March 4-7, 2010.

Source
Sorin Group